{"id":14612,"date":"2021-04-30T08:47:49","date_gmt":"2021-04-30T06:47:49","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=14612"},"modified":"2024-12-11T13:14:30","modified_gmt":"2024-12-11T12:14:30","slug":"traitement-de-maintenance-par-azacytidine-orale-dans-les-lam-traitement-de-maintenance-par-azacytidine-orale-dans-les-lam","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/traitement-de-maintenance-par-azacytidine-orale-dans-les-lam-traitement-de-maintenance-par-azacytidine-orale-dans-les-lam\/","title":{"rendered":"Traitement de maintenance par azacytidine orale dans les LAM"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1302px;margin-left: calc(-5% \/ 2 );margin-right: calc(-5% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.375%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.375%;--awb-width-medium:100%;--awb-spacing-right-medium:2.375%;--awb-spacing-left-medium:2.375%;--awb-width-small:100%;--awb-spacing-right-small:2.375%;--awb-spacing-left-small:2.375%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><div><span lang=\"EN-US\">R\u00e9f. : HematoStat.net ; 2 (1) : R12<\/span><\/div>\n<div><\/div>\n<div><em><strong><span lang=\"EN-US\">Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission<\/span><\/strong><\/em><\/div>\n<div><\/div>\n<div>\n<div><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33369355\/\"><i><span lang=\"EN-US\">Wei, A. H. et al. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N. Engl. J. Med. 383, 2526\u20132537 (2020).<\/span><\/i><\/a><\/div>\n<\/div>\n<div><\/div>\n<h3>R\u00e9sum\u00e9 :<\/h3>\n<div>Apr\u00e8s l\u2019obtention d\u2019une r\u00e9mission compl\u00e8te (RC), la majorit\u00e9 des patients atteints de leuc\u00e9mie aigu\u00eb my\u00e9lo\u00efde (LAM) in\u00e9ligibles \u00e0 une allogreffe va rechuter. L\u2019essai de phase 3 QUAZAR AML-001 a permis d\u2019inclure 472 patients \u00e2g\u00e9s de 55 \u00e0 86 ans. Les patients en RC apr\u00e8s une chimioth\u00e9rapie intensive (type 3+7) recevaient le CC-486, agent hypom\u00e9thylant oral, ou un placebo pendant 2 ans. La survie m\u00e9diane \u00e9tait de 24,7 mois dans le bras exp\u00e9rimental contre 14,8 mois (p&lt;0,001).<\/div>\n<div><\/div>\n<div>\n<h3>Dans nos pratiques :<\/h3>\n<p>Cette publication confirme les r\u00e9sultats pr\u00e9sent\u00e9s \u00e0 l\u2019ASH en 2019 avec pour la premi\u00e8re fois un b\u00e9n\u00e9fice en terme de survie pour un traitement de maintenance dans cette population. Cette mol\u00e9cule, sans bio\u00e9quivalence avec la forme parent\u00e9rale, semble bien tol\u00e9r\u00e9e et offre une option suppl\u00e9mentaire pour les patients non \u00e9ligibles \u00e0 une consolidation par allogreffe et on pense notamment au LAM de pronostic interm\u00e9diaire qui ne dispose pas de mutations \u00ab ciblables \u00bb.<\/p>\n<h3><strong>Le regard du statisticien :<\/strong><\/h3>\n<p>La pr\u00e9sentation des r\u00e9sultats de cette \u00e9tude de phase 3 a pris une tournure particuli\u00e8re. Initialement pr\u00e9vu pour donner des r\u00e9sultats sous forme de hazard-ratios, les auteurs ont d\u00fb trouver une autre solution pour \u00e9voquer l\u2019int\u00e9r\u00eat de l\u2019agent oral en termes de survie car l\u2019hypoth\u00e8se de proportionnalit\u00e9 des risques \u00e9tait viol\u00e9e. Le choix a \u00e9t\u00e9 fait et valid\u00e9 de pr\u00e9senter les r\u00e9sultats \u00e0 travers les m\u00e9dianes de survie et un <em>forest plot <\/em>de la diff\u00e9rence de survie \u00e0 2 ans. Cela pourra faire office de \u00ab jurisprudence \u00bb.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":16,"featured_media":14595,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[36],"tags":[68,61,6,69,70],"ppma_author":[456],"class_list":["post-14612","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-revue-de-presse","tag-azacitidine-per-os","tag-lam","tag-leucemies-aigues","tag-maintenance","tag-quazar","author-alexis-genthon"],"aioseo_notices":[],"authors":[{"term_id":456,"user_id":16,"is_guest":0,"slug":"alexis-genthon","display_name":"Alexis GENTHON","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png"},"first_name":"","last_name":"","user_url":"","description":"H\u00e9matologue.\r\nCorrespondance : H\u00f4pital Saint-Antoine \r\nService h\u00e9matologie clinique\r\n184 rue du Faubourg Saint-Antoine 75012 Paris."}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/14612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=14612"}],"version-history":[{"count":1,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/14612\/revisions"}],"predecessor-version":[{"id":18179,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/14612\/revisions\/18179"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=14612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=14612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=14612"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=14612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}